Literature DB >> 28813176

Validating the Concept of COPD Control: A Real-world Cohort Study from the United Kingdom.

Anjan Nibber1, Alison Chisholm1, Juan José Soler-Cataluña2,3, Bernardino Alcazar4, David Price5, Marc Miravitlles3,6.   

Abstract

The concept of Chronic Obstructive Pulmonary Disease (COPD) control has been developed to inform therapeutic decision-making. We explored the validity of a definition of COPD control in a representative population of patients with COPD in the United Kingdom. Electronic medical records and linked COPD questionnaire data from the Optimum Patient Care Research Database were used to characterize control status. Patients were aged ≥40 years, with spirometry-confirmed COPD, current or ex-smokers, and continuous records throughout the study period. Control was evaluated based on COPD stability and patients' (i) clinical features or (ii) COPD Assessment Test (CAT) score over a three-month baseline period and linked to time to first exacerbation. Of 2788 eligible patients, 2511 (90%) had mild/moderate COPD and 277 (10%) had severe/very severe COPD based on Body Mass Index, Obstruction, Dyspnoea, Exacerbations (BODEx) cut-off of 4. Within the mild/moderate cohort, 4.5% of patients were controlled at baseline according to clinical features and 21.5% according to CAT threshold of 10. Within the severe/very severe cohort, no patients were controlled at baseline according to the proposed clinical features and 8.3% were controlled according to CAT threshold of 20. Compared with uncontrolled patients, time to first exacerbation was longer for controlled patients with mild/moderate COPD but not for those with severe/very severe COPD. Lowering the BODEx threshold for severity classification to 2 increased the number of patients achieving control. CAT scores were not good predictors of the risk of future exacerbation. With the proposed definition, very few patients were defined as controlled.

Entities:  

Keywords:  Chronic Obstructive Pulmonary Disease (COPD); control; impact; stability; validation

Mesh:

Year:  2017        PMID: 28813176     DOI: 10.1080/15412555.2017.1350154

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  6 in total

Review 1.  Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis.

Authors:  Marc Miravitlles; Gerard Urrutia; Alexander G Mathioudakis; Julio Ancochea
Journal:  Respir Res       Date:  2017-11-25

2.  Characteristics and health related quality of life in a population with advanced chronic obstructive pulmonary disease, a cross-sectional study.

Authors:  D G Bove; M Lavesen; B Lindegaard
Journal:  BMC Palliat Care       Date:  2020-06-18       Impact factor: 3.234

3.  Degree of control of patients with chronic obstructive pulmonary disease in Spain: SINCON study.

Authors:  Adolfo Baloira; José Miguel Rodriguez Gonzalez-Moro; Estefanía Sanjuán; Juan Antonio Trigueros; Ricard Casamor
Journal:  BMC Pulm Med       Date:  2018-12-03       Impact factor: 3.317

4.  Validation of clinical control in COPD as a new tool for optimizing treatment.

Authors:  Juan José Soler-Cataluña; Maribel Marzo; Pablo Catalán; Cristina Miralles; Bernardino Alcazar; Marc Miravitlles
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-11-14

5.  Clinical Control Criteria to Determine Disease Control in Patients with Severe COPD: The CLAVE Study.

Authors:  Juan José Soler-Cataluña; Pere Almagro; Arturo Huerta; Diego González-Segura; Borja G Cosío
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-01-25

6.  Relationship Between Clinical Control, Respiratory Symptoms and Quality of Life for Patients with COPD.

Authors:  Bernardino Alcazar-Navarrete; Antonia Fuster; Patricia García Sidro; Juan Luis García Rivero; Beatriz Abascal-Bolado; Abel Pallarés-Sanmartín; Eduardo Márquez; Agustin Valido-Morales; Ana Boldova Loscertales; Francisco Javier Callejas-Gonzalez; Marta Palop; Juan Antonio Riesco; Rafael Golpe; Juan Jose Soler-Cataluña; Marc Miravitlles
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-10-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.